Proactive Investors - Run By Investors For Investors

New Redx CEO bringing leadership and skills to 'capitalise on its great science'

Lisa Anson, the new chief executive at Redx Pharma Plc (LON:REDX), sat down with Proactive's Andrew Scott just weeks after taking on the new role.

Anson was the president of AstraZeneca PLC’s (LON:AZN) UK division immediately prior to joining, while she's also held various other senior leadership roles during her 20-year career at the FTSE 100-drugs giant.

The first patient in a Phase I/II trial for Redx's lead drug RXC004 was dosed back in February but they paused the study just over a month later, admitting that the dosing levels it had thought were right based on pre-clinical research were actually too high.

Since then it has been talking with regulators about lowering the dose and getting the trial back up and running again which it expects will happen in the first half of 2019.

 
Meet Cardinal Resources Ltd and Legend Mining Ltd at our event, Melbourne , 16 July 2019. Register here »
View full REDX profile View Profile

Redx Pharma Plc Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use